Impact of asymptomatic sexually transmitted infections and interferon agonists on the susceptibility of foreskin primary cells to HIV-1 infection.

无症状性传播感染和干扰素激动剂对包皮原代细胞对 HIV-1 感染易感性的影响。

基本信息

项目摘要

Project Summary/Abstract Understanding the mechanisms involved in HIV acquisition and transmission is critical for novel prevention strategies. The understanding of early events in HIV-1 acquisition and expansion of the virus remains incomplete, especially in males. The incidence of sexually transmitted infections (STI’s) can increase HIV-1 acquisition risk, and there exist gaps in understanding the mechanisms also. This study will exploit the medical male circumcision (MMC) roll out in South Africa, which facilitates the collection of otherwise discarded foreskins to characterize male genital tissue-resident HIV-1 target cells. Dr Chigorimbo-Tsikiwa will characterize the molecular and functional interactions between HIV-1 , lymphoid and myeloid target cells from the FS. A uniqueness of the proposed study lies in interrogating how in vivo activating events from bacterial STIs can modulate ex vivo HIV-1 target cell susceptibility. We hypothesize that foreskin tissue contains several cell lineages that are susceptible to HIV-1 infection that can support viral expansion and that the increased inflammatory response induced by asymptomatic STIs will exacerbate this susceptibility. Aim 1 will investigate the phenotypic and transcriptomic profiles between lymphoid and myeloid cells isolated from the foreskin tissues from men with and without asymptomatic bacterial STIs. Aim 2, will determine the impact of immune activation on the susceptibility of lymphoid and myeloid cells to HIV-1 infection. Dr Chigorimbo-Tsikiwa will challenge foreskin-derived cells with a panel of HIV-1 isolates to assess the relative susceptibility of characterized cells to HIV-1 infection. We will explore the impact of in vivo immune activation by performing HIV-1 challenge on cells isolated from STI-positive individuals as well as to in vitro activation using Chlamydia antigens, LPS and TLR agonists on viral infectivity and expansion. Interferon stimulated genes, (ISG’s) antagonists have been shown to confer an antiviral state in cells and against other retroviruses. Therefore, aim 3 will assess the repurposing of bis-arylidenecycloalkanones as ISG agonist for use as anti -HIV-1 molecules in various cell models. This research study based from human foreskins will provide novel insights in HIV acquisition and transmission in the male genital tract and increase knowledge in the field which will facilitate the research career development of Dr Chigorimbo- Tsikiwa. Dr Chigorimbo-Tsikiwa will receive mentorship from lead researchers who are prolific publishers, possess several research grants in infectious disease biomedical research who have mentored approximately 40 post-docs between them in Dr David Russell at Cornell University, Dr Frank Kirchhoff at Ulm University in Germany and Dr Clive Gray in South Africa. This study will allow Dr Chigorimbo-Tsikiwa access to high technology driven research in three continents afforded by her mentorship relationships during this K award spring boarding her as an independent African HIV biomedical scientist.
项目总结/摘要 了解艾滋病毒获得和传播的机制对于新的预防至关重要 战略布局对HIV-1感染和病毒扩散早期事件的理解仍然存在 不完整,尤其是男性。性传播感染(STI)的发病率可以增加HIV-1 采购风险,在了解机制方面也存在差距。这项研究将利用 医疗男性包皮环切术(MMC)在南非推出,这有助于收集其他 丢弃的包皮来表征男性生殖器组织驻留的HIV-1靶细胞。Chigorimbo-Tsikiwa博士 将描述HIV-1、淋巴和骨髓靶细胞之间的分子和功能相互作用 从FS。所提出的研究的一个独特之处在于询问体内激活事件是如何从 细菌性STI可以调节离体HIV-1靶细胞的易感性。我们假设包皮组织 含有几种易受HIV-1感染的细胞谱系,可支持病毒扩增, 无症状性传播感染引起的炎症反应增加将加剧这种易感性。 目的1将研究淋巴细胞和髓细胞之间的表型和转录谱 分离自患有和不患有无症状细菌性STI的男性的包皮组织。目标二,威尔 确定免疫激活对淋巴细胞和骨髓细胞对HIV-1易感性的影响 感染Chigorimbo-Tsikiwa博士将用一组HIV-1分离物挑战包皮衍生细胞, 评估表征细胞对HIV-1感染的相对易感性。我们将探讨在 通过对分离自STI阳性个体的细胞进行HIV-1攻击, 关于使用衣原体抗原、LPS和TLR激动剂对病毒感染性和扩增的体外活化。 干扰素刺激基因(ISG)拮抗剂已显示在细胞中赋予抗病毒状态, 对抗其他逆转录病毒因此,目标3将评估双亚芳基环烷酮的再利用, 在各种细胞模型中用作抗HIV-1分子的ISG激动剂。这项研究基于人类 包皮将提供新的见解艾滋病毒的收购和传播的男性生殖道, 增加该领域的知识,这将有助于Chigorimbo博士的研究职业发展- 齐基瓦Chigorimbo-Tsikiwa博士将接受来自多产出版商的主要研究人员的指导, 在传染病生物医学研究方面拥有多项研究赠款, 大约有40名博士后,康奈尔大学的大卫罗素博士, 德国的乌尔姆大学和南非的克莱夫格雷博士。这项研究将使奇戈林博-齐基瓦博士 通过她的导师关系,她可以在三大洲获得高科技驱动的研究 在这个K奖春季寄宿她作为一个独立的非洲艾滋病毒生物医学科学家。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nyaradzo Tsitsi Chigorimbo-Tsikiwa其他文献

Nyaradzo Tsitsi Chigorimbo-Tsikiwa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nyaradzo Tsitsi Chigorimbo-Tsikiwa', 18)}}的其他基金

Impact of asymptomatic sexually transmitted infections and interferon agonists on the susceptibility of foreskin primary cells to HIV-1 infection.
无症状性传播感染和干扰素激动剂对包皮原代细胞对 HIV-1 感染易感性的影响。
  • 批准号:
    10456919
  • 财政年份:
    2020
  • 资助金额:
    $ 1.51万
  • 项目类别:
Impact of asymptomatic sexually transmitted infections and interferon agonists on the susceptibility of foreskin primary cells to HIV-1 infection.
无症状性传播感染和干扰素激动剂对包皮原代细胞对 HIV-1 感染易感性的影响。
  • 批准号:
    10912958
  • 财政年份:
    2020
  • 资助金额:
    $ 1.51万
  • 项目类别:
Development of an HIV infection model of human foreskin to obtain novel insights into virus transmission
开发人类包皮艾滋病毒感染模型以获得对病毒传播的新见解
  • 批准号:
    10918395
  • 财政年份:
    2020
  • 资助金额:
    $ 1.51万
  • 项目类别:
Impact of asymptomatic sexually transmitted infections and interferon agonists on the susceptibility of foreskin primary cells to HIV-1 infection.
无症状性传播感染和干扰素激动剂对包皮原代细胞对 HIV-1 感染易感性的影响。
  • 批准号:
    10053750
  • 财政年份:
    2020
  • 资助金额:
    $ 1.51万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 1.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 1.51万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 1.51万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 1.51万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 1.51万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 1.51万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 1.51万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 1.51万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 1.51万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 1.51万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了